Roche (ROG) Given a CHF 305 Price Target at Barclays

Roche (VTX:ROG) has been given a CHF 305 price objective by equities research analysts at Barclays in a research note issued on Wednesday, December 27th. The firm currently has a “buy” rating on the healthcare company’s stock. Barclays’ target price points to a potential upside of 24.08% from the company’s current price.

A number of other brokerages have also recently weighed in on ROG. Sanford C. Bernstein set a CHF 262 price target on shares of Roche and gave the company a “buy” rating in a research report on Friday, December 1st. Morgan Stanley set a CHF 260 price target on shares of Roche and gave the company a “neutral” rating in a research report on Friday, December 1st. Deutsche Bank set a CHF 254 price target on shares of Roche and gave the company a “neutral” rating in a research report on Thursday, November 23rd. Liberum Capital set a CHF 279 price target on shares of Roche and gave the company a “buy” rating in a research report on Wednesday, November 22nd. Finally, Goldman Sachs Group set a CHF 325 price target on shares of Roche and gave the company a “buy” rating in a research report on Thursday, December 7th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. Roche currently has an average rating of “Hold” and a consensus price target of CHF 263.42.

Roche (ROG) traded up CHF 1.30 during trading on Wednesday, reaching CHF 245.80. 1,680,000 shares of the company were exchanged, compared to its average volume of 1,550,000. The stock has a market capitalization of $212,060.00 and a P/E ratio of 21.85. Roche has a 52-week low of CHF 226.10 and a 52-week high of CHF 273.

WARNING: “Roche (ROG) Given a CHF 305 Price Target at Barclays” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/barclays-analysts-give-roche-rog-a-chf-305-price-target.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply